The Cyclics Corporation have issued details of their first commercial product grades, and have also initiated a search for a second, world scale plant for the production of CBT resin.
CBT 100 resin and CBT 200 resin both melt to a water-like viscosity when heated then polymerize into the engineering thermoplastic polybutylene terephthalate (PBT) when catalyzed. CBT 100 resin has a processing temperature between 190-240C and will be available in both one and two-part systems.
This resin is formulated for compounding, injection moulding, nanocomposites, rotational moulding and as a carrier resin for colour and filler concentrates. For applications requiring a lower processing temperature, CBT 200 resin has a processing range between 170-240C and also is available in both one- and two-part systems. CBT 200 resin is formulated for various casting, low pressure moulding, coatings and composite applications where the lower melt temperature allows for longer working time than CBT 100 resin before polymerizing into the engineering thermoplastic PBT.
Several additional grades from these two products are under development, including flame retardant, food & medical contact, and high modulus grades. Flame retardant grades are targeted towards the electronics market and fuel tank applications. Medical & food grade developments centre on pigment concentrates and nano-composites for medical devices and food contact applications. High modulus grades are designed to have greater stiffness and dimensional stability over a wider range of temperatures as needed in more demanding applications.
“These new products will enable our customers to seize opportunities in markets that were unobtainable before the introduction of CBT resin,” said John Ciovacco, Head of Global Marketing for Cyclics Corporation. “Our ongoing efforts to broaden our product line through additives technology, reinforcing materials and copolymers will further expand our reach.”
Cyclics have also commenced a formal search to site a second, world scale plant for the production of CBT resin. Although the search currently is focused primarily in North America and Europe, other regions will also be considered. Proximity to raw materials, low raw material and energy costs, availability of skilled labour, good transportation routes and attractive financial incentives are among the key criteria Cyclics is evaluating for siting the second plant.
The announcement comes as Cyclics nears completion of its first commercial plant, with a capacity of 2500 metric tonnes (5.5 million pounds). Located in Schwarzheide, Germany, the plant is scheduled to be producing commercial products in the first quarter of 2005. Greater than 50% of the initial nameplate capacity is under contract and a strong pipeline of development projects has led Cyclics to take steps to double the capacity to 5000 metric tonnes (10 million pounds) at the Schwarzheide plant late in 2005.
“The tremendous growth in demand we are seeing for our products has given us the confidence to launch this search,” said Ted Eveleth, CEO of Cyclics Corporation. “We are experiencing very encouraging developments in high-volume applications.”
“It is exciting to see the Schwarzheide plant nearing completion,” said Dr. Gary Faler, Chief Technology Officer of Cyclics Corporation, “Our enthusiasm is shared by our customers who have played an invaluable role in helping us develop our first commercial products, our financial backers who have financed the plant and all of our employees in both North America and Europe.”
For more information visit:
Subscribe to receive our weekly round-up of all the industry's latest news, jobs, events and more!